IP Library Granted Patent US 11,339,145
Granted Patent B2
US 11,339,145 · App. 17/076,356 · Granted May 24, 2022

Synthesis of cerdulatinib

Inventors: Anjali Pandey (Fremont, CA); Arvinder Sran (Fremont, CA); Ying Chen (Thousand Oaks, CA); Daniele Poggiali (Lugano, CH); Tiziano Fumagalli (Lipomo, IT)
Assignee: Alexion Pharmaceuticals, Inc.
C07D403/12C07D239/42C07D239/47C07D239/48
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,339,145
App. No.
17/076,356
Granted
May 24, 2022
Kind
B2
Abstract

The present disclosure provides processes for the preparation of cerdulatinib, which is of formula I: or a salt thereof. The disclosure also provides intermediates and processes for the preparation of the intermediates useful in the preparation of cerdulatinib or a salt thereof.

Claims (21)

1. A process for preparing Compound A, wherein Compound A is Compound A-2, a salt of Compound A-2, Compound A-3, a salt of Compound A-3, or a mixture thereof:

wherein the process comprises contacting Compound C:

or a salt thereof with an oxidizing agent;

wherein Compound C is prepared by contacting Compound D-1:

or a salt thereof with formamide and sodium ethoxide.

2. The process of claim 1 , wherein the oxidizing agent is meta-chloroperoxybenzoic acid.

3. The process of claim 1 , wherein a molar ratio of the oxidizing agent to Compound C is about 2:1 to about 4:1.

4. The process of claim 1 , wherein a molar ratio of the oxidizing agent to Compound C is about 2.5:1 to about 3.5:1.

5. The process of claim 1 , wherein a molar ratio of the oxidizing agent to Compound C is about 1.1:1 to about 2:1.

6. The process of claim 1 , wherein the contacting of Compound C or the salt thereof with the oxidizing agent is at a temperature of about −10° C. to about 20° C.

7. The process of claim 1 , wherein the contacting of Compound C or the salt thereof with the oxidizing agent is in a first solvent.

8. The process of claim 7 , wherein the first solvent is N-methylpyrrolidone (NMP).

9. The process of claim 1 , wherein Compound D-1 is prepared by a method comprising contacting Compound K

or a salt thereof with cyclopropylamine or a salt thereof to form Compound D-1.

10. The process of claim 1 , wherein formamide and Compound D-1 are in a molar ratio of about 5:1 to about 15:1.

11. The process of claim 1 , wherein the contacting of Compound D-1 with formamide and sodium ethoxide is in a second solvent.

12. The process of claim 11 , wherein the second solvent is THF.

13. The process of claim 1 , wherein the contacting of Compound D-1 with formamide and sodium ethoxide is at a temperature of about 0° C. to about 10° C.

14. The process of claim 1 , wherein the contacting of Compound D-1 with formamide and sodium ethoxide is for about 10 to about 24 hours.

15. A compound

or a salt thereof prepared by the process of claim 1 .

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 14, 2021
From: PORTOLA PHARMACEUTICALS, LLC
To: ALEXION PHARMACEUTICALS, INC.
Reel/Frame 054999/0218 →
CHANGE OF NAME Recorded Jan 12, 2021
From: PORTOLA PHARMACEUTICALS, INC.
To: PORTOLA PHARMACEUTICALS, LLC
Reel/Frame 054975/0183 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 15, 2020
From: PANDEY, ANJALI; SRAN, ARVINDER; CHEN, YING; POGGIALI, DANIELE; FUMAGALLI, TIZIANO
To: PORTOLA PHARMACEUTICALS, INC.
Reel/Frame 054643/0744 →